OpenEvidence raised $250 million at a $15 billion price, according to Business Insider on September 24, 2026, in a round backed by hospital systems and Andreessen Horowitz. That surge puts the OpenEvidence valuation among the highest in health AI and up from a reported $12 billion in January. It also hints at a new center of gravity: hospitals are no longer just buyers of AI—they’re writing the checks that set the price.
Why the OpenEvidence valuation jumped to $15B
Business Insider reports the company positions itself as an AI search engine for doctors and, per people familiar with the matter, could even be open to a sale if access to computing becomes a constraint. The OpenEvidence valuation reflects three bets investors appear to be making. First, clinical query tools that return citations can win trust faster than free-form chatbots in medicine. Second, health systems as investors can speed procurement and integration. Third, scarce compute will advantage firms that secure long-term capacity contracts now.
There’s precedent for big numbers in this space, but not many private startups have reached them. Microsoft completed its purchase of Nuance—whose voice tech is embedded across hospitals—for $19.7 billion in March 2022, underscoring how clinical workflow control commands premium prices (Microsoft). Seen through that lens, a $15 billion private mark assumes OpenEvidence can become a critical workflow node, not just a smart search bar.
What $250M from hospitals means inside the clinic
According to Business Insider, hospital systems joined the round. That matters. Provider-backed capital isn’t just money; it’s distribution, integration time, and clinician champions. Tools that shave minutes from a consult or cut after-hours charting tend to survive budget reviews. A recent wave of ambient documentation rollouts shows how quickly an AI that fits the visit can spread across a system. Epic’s work with Abridge, for example, has pushed AI scribe tools deeper into mainstream EHR workflows (STAT).
For OpenEvidence, hospital participation may shorten pilots, accelerate governance reviews, and surface specialty-specific needs earlier. If it lands in oncology tumor boards, hospitalist handoffs, or perioperative checklists, the OpenEvidence valuation starts to look less like froth and more like a bet on embedded decision support. That is where clinical AI earns renewals.
The $15 billion price tag and FDA oversight risk
How a product is framed in the chart matters as much as the model behind it. The FDA’s Clinical Decision Support guidance draws a line: software that displays information and lets the clinician independently review the basis for the recommendation faces lighter oversight; software that effectively drives diagnosis or treatment decisions can fall under device rules. Business Insider describes OpenEvidence as an evidence search engine for doctors. That positioning suggests a path with fewer regulatory hurdles—if the product stays there.
Cross the line into prescriptive advice, and the organization must invest in quality systems, postmarket surveillance, and change management for every model update. Those are solvable tasks, but they add time and cost. A $15 billion mark prices in the assumption that the company can scale value while staying on the safer side of that boundary, or it can clear the bar for device-grade software when needed.
Compute pressure may shape M&A options
Business Insider also reports the company could be open to selling, specifically to secure compute. That’s a telling admission. As models grow and usage shifts from pilots to daily practice, inference costs can dominate gross margin. Capacity is not just about GPUs in a rack; it’s about siting data centers, local permits, and power. Some regions have already tightened data center growth, signaling a slower buildout in critical markets (Reuters on Ireland’s restrictions). The IEA forecasts rising electricity demand from data centers as well, which pushes long-term costs higher.
In that environment, strategic owners with cloud, chips, and routes to patient data—big tech, large EHR vendors, or payer-provider platforms—gain leverage. If compute scarcity bites, an acquirer that can guarantee capacity and compliance controls starts to look less like a trade sale and more like operational infrastructure. The OpenEvidence valuation, then, partially reflects an embedded option on future access to scale compute.
What hospital CIOs should watch next
Three checkpoints will test whether the OpenEvidence valuation holds:
- Embedded workflow wins: Does the product move beyond generic search into specialty pathways where decisions hinge on guidelines and up-to-date trials? Clear, source-linked answers that clinicians can audit are table stakes in high-risk settings.
- EHR integration depth: Partnerships that bring context from the patient chart—medication lists, labs, problems—without creating safety hazards will determine whether this stays a tool clinicians open, or a layer the EHR calls. Watch for formal integrations and measured latency.
- Cost curve and reliability: As adoption rises, can the company keep answers fast and bills predictable? That depends on model efficiency, retrieval quality, and compute contracts. In a world of tight margins, inference surprises kill deployments.
Investors have paid up for this playbook before. Nuance fetched a near-$20 billion price because it lived inside clinical work and reduced after-hours typing, not because it dazzled in demos (Microsoft). If OpenEvidence can become the first stop for evidence at the point of care—and show measurable gains in accuracy or time saved—the $15 billion mark starts to make sense.
According to Business Insider, it remains unclear whether the company will sell or stay independent. Either way, the signal is clear: providers want a say in the AI tools that reach their wards. That alone makes this financing different from the average venture round.
The market will now look for proof. Contracted pilots across multiple service lines, published evaluations with outcome deltas, and durable compute plans will tell us whether this is an early peek at a new clinical utility—or a price that got ahead of the workload. For now, the OpenEvidence valuation sets a bar that other health AI companies will be measured against.